Table 5.
Hazard Ratio (95% CI) | |||||||
---|---|---|---|---|---|---|---|
PBUT | Outcome | N | # Events | Model I | P | Model II | P |
Kynurenine (µmol/L) |
All-cause mortality | 79 | 34 | 1.020 (0.802 to 1.298) | 0.872 | 0.943 (0.707 to 1.256) | 0.687 |
CV events | 78 | 29 | 1.054 (0.807 to 1.376) | 0.701 | 0.982 (0.717 to 1.346) | 0.911 | |
Kynurenic acid (µmol/L) | All-cause mortality | 80 | 35 | 0.879 (0.638 to 1.210) | 0.429 | 1.104 (0.666 to 1.829) | 0.702 |
CV events | 79 | 29 | 0.876 (0.622 to 1.235) | 0.876 | 1.333 (0.798 to 2.226) | 0.272 | |
Indoxyl sulfate (µmol/L) | All-cause mortality | 80 | 35 | 1.001 (0.995 to 1.006) | 0.837 | 1.002 (0.995 to 1.009) | 0.617 |
CV events | 79 | 29 | 1.003 (0.998 to 1.008) | 0.290 | 1.007 (1.000 to 1.015) | 0.056 | |
Indole-3-acetic acid (µmol/L) | All-cause mortality | 60 | 24 | 1.190 (0.609 to 2.323) | 0.610 | 1.346 (0.568 to 3.192) | 0.500 |
CV events | 59 | 20 | 1.002 (0.493 to 2.039) | 0.995 | 1.434 (0.535 to 3.847) | 0.474 | |
p-Cresyl sulfate (µmol/L) | All-cause mortality | 80 | 35 | 0.955 (0.670 to 1.362) | 0.801 | 0.897 (0.614 to 1.310) | 0.574 |
CV events | 79 | 29 | 0.960 (0.664 to 1.389) | 0.829 | 1.036 (0.667 to 1.611) | 0.874 | |
p-Cresyl glucuronide (µmol/L) | All-cause mortality | 80 | 35 | 0.992 (0.767 to 1.283) | 0.952 | 1.024 (0.782 to 1.340) | 0.864 |
CV events | 79 | 29 | 1.032 (0.775 to 1.374) | 0.830 | 1.189 (0.863 to 1.636) | 0.289 | |
Hippuric acid (µmol/L) |
All-cause mortality | 78 | 33 | 1.037 (0.688 to 1.562) | 0.862 | 0.966 (0.569 to 1.642) | 0.900 |
CV events | 77 | 28 | 0.722 (0.457 to 1.142) | 0.164 | 0.823 (0.445 to 1.524) | 0.536 |
Uni/Multivariate Cox proportional hazards regression analysis censored for kidney transplantation. Model I: univariate; model II: adjustment for age, gender, diabetes mellitus, history of cardiovascular disease, renal creatinine clearance and normalized protein nitrogen appearance. Data are expressed as hazard ratios with 95% confidence interval (CI) and p-value for the occurrence of new cardiovascular (CV) events and all-cause mortality associated with a one-unit increase in PBUT plasma concentration.